Regeneron Pharmaceuticals is conducting a Phase 2 clinical study titled A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic ...

A new study, presented as a late-breaking poster, demonstrates proof of concept for a continuous protein sensor as a tool to prevent muscle loss during GLP-1 therapy.

Regeneron has asserted the ’865 patent in BPCIA litigations against Mylan, Samsung Bioepis, Celltrion, Formycon, and Amgen.

A new Concordia study suggests that aquatic therapy for individuals with chronic low back pain can do more than strengthen the muscles around the spine. It can also have a beneficial impact on the ...

Yet Another Study Finds That AI Is Making Us Dumb LLM users displayed the "weakest" brain connectivity in a new MIT study that hints AI use harms critical thinking.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc.

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones.

Thinking about taking Ozempic but worried about losing too much muscle? New clinical trial data might point to a future where that’s no longer a concern. Regeneron Pharmaceuticals announced the ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Monday reported interim results from the ongoing Phase 2 COURAGE study evaluating semaglutide and trevogrumab with or without garetosmab for the ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...